Charles Schwab’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Charles Schwab’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,319	Closed	-$52K	–	3565
2022 Q2	$52K	Hold	12,319	–	–	﹤0.01%	3389
2022 Q1	$47K	Hold	12,319	–	–	﹤0.01%	3537
2021 Q4	$56K	Hold	12,319	–	–	﹤0.01%	3504
2021 Q3	$58K	Sell	12,319 -22,008	-64%	-$117K	﹤0.01%	3434
2021 Q2	$243K	Sell	34,327 -21,558	-39%	-$116K	﹤0.01%	3260
2021 Q1	$331K	Buy	55,885 +1,780	+3%	+$10.8K	﹤0.01%	3218
2020 Q4	$250K	Sell	54,105 -941	-2%	-$4.06K	﹤0.01%	3228
2020 Q3	$215K	Buy	55,046 +9,601	+21%	+$193K	﹤0.01%	3156
2020 Q2	$1.31M	Buy	45,445 +15,570	+52%	+$360K	﹤0.01%	2554
2020 Q1	$643K	Sell	29,875 -3,640	-11%	-$82.6K	﹤0.01%	2625
2019 Q4	$660K	Buy	+33,515	New	+$476K	﹤0.01%	2722

Other funds holding STSA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab's STSA Position: Q3 2022 in Review

Charles Schwab sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2022, closing a stake of 12,319 shares — an estimated $52K sold.

Charles Schwab first reported a position in STSA in Q4 2019 and held it in 11 quarters. The position peaked at $1.31M in Q2 2020. 41 funds tracked by Wall St. Rank hold STSA as of Q3 2022.

Charles Schwab reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Charles Schwab sold 12,319 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $52K.
Charles Schwab first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Charles Schwab's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $1.31M in Q2 2020.
41 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.